TRXB: The $1.1B Eli Lilly Bet Wall Street Missed
TRex Bio (TRXB) secures $202M cash runway into 2029 — biotech stock analysis
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down TRex Bio, Inc. (TRXB) and its proprietary Deep Biology platform targeting tissue-resident regulatory T cells for chronic inflammatory conditions. With a post-IPO pro forma cash position of over $195 million funding operations into the second half of 2029, the key question for investors is…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.